Plus   Neg

FibroGen Inc. (FGEN) Has Soared To A New High On Phase 2 Study News

FibroGen Inc. (FGEN) announced after the bell Monday that its Phase 2 study of pamrevlumab in patients with idiopathic pulmonary fibrosis met the primary efficacy endpoint.

FibroGen has gapped open dramatically higher Tuesday morning and is now up 16.55 at $49.95 on strong volume. The stock has soared to a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT